Skip to main content
Top
Published in: Journal of General Internal Medicine 5/2018

Open Access 01-05-2018 | Capsule Commentary

Capsule Commentary on Bremmer et. al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations

Author: Alexander G. Mathioudakis, MD, MRCP(UK)

Published in: Journal of General Internal Medicine | Issue 5/2018

Login to get access

Excerpt

Recent data reveal an alarming 50% increase in mean antimicrobial resistance within the last decade, across the OECD member countries.1 Moreover, the results of extensive campaigns against inappropriate antibiotic prescribing are only modest,2 emphasizing the need for alternative, effective stewardship methods. Serum procalcitonin, being able to differentiate bacterial versus viral infections or non-specific inflammation, is increasingly and successfully used to guide the initiation and/or discontinuation of antibiotics from primary to intensive care settings.3
Literature
2.
go back to reference Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543.PubMed Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543.PubMed
3.
go back to reference Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017;26(143). Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017;26(143).
4.
go back to reference Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–96.CrossRefPubMed Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–96.CrossRefPubMed
5.
go back to reference Bremmer DN, DiSilvio BE, Hammer C, Beg M, Vishwanathan S, Speredelozzi D, Moffa MA, Hu K, Abdulmassih R, Makadia JT, Sandhu R, Naddour M, Chan-Tompkins NH, Trienski TL, Watson C, Obringer TJ, Kuzyck J, Walsh TL (2018) Impact of procalcitonin guidance on management of adults hospitalized with chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. https://doi.org/10.1007/s11606-018-4312-2 Bremmer DN, DiSilvio BE, Hammer C, Beg M, Vishwanathan S, Speredelozzi D, Moffa MA, Hu K, Abdulmassih R, Makadia JT, Sandhu R, Naddour M, Chan-Tompkins NH, Trienski TL, Watson C, Obringer TJ, Kuzyck J, Walsh TL (2018) Impact of procalcitonin guidance on management of adults hospitalized with chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. https://​doi.​org/​10.​1007/​s11606-018-4312-2
Metadata
Title
Capsule Commentary on Bremmer et. al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations
Author
Alexander G. Mathioudakis, MD, MRCP(UK)
Publication date
01-05-2018
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 5/2018
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-018-4341-x

Other articles of this Issue 5/2018

Journal of General Internal Medicine 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine